Table 1 Clinic and pathologic features of 78 NSCLC patients receiving immunotherapy and opioids
Characteristics | Total | NLR-Low | NLR-High | P | PLR-Low | PLR-High | P | SII/ALB-Low | SII/ALB-High | P |
|---|---|---|---|---|---|---|---|---|---|---|
N = 78(%) | N = 47(%) | N = 31(%) | N = 49(%) | N = 29(%) | N = 37(%) | N = 41(%) | ||||
Sex | ||||||||||
Female | 27(34.6) | 16(34) | 11(35.5) | 0.896 | 15(30.6) | 12(41.4) | 0.334 | 15(40.5) | 12(29.3) | 0.296 |
Male | 51(65.4) | 31(66) | 20(64.5) | 34(69.4) | 17(58.6) | 22(59.5) | 29(70.7) | |||
Age | ||||||||||
≤ 60 | 32(41) | 18(38.3) | 14(45.2) | 0.546 | 19(38.8) | 13(44.8) | 0.599 | 18(48.6) | 14(34.1) | 0.194 |
>60 | 46(59) | 29(61.7) | 17(54.8) | 30(61.2) | 16(55.2) | 19(51.4) | 27(65.9) | |||
Histological types | ||||||||||
SCC | 26(33.3) | 19(40.4) | 7(22.6) | 0.102 | 17(34.7) | 9(31) | 0.740 | 17(45.9) | 9(22%) | 0.025 |
Non-SCC | 52(66.7) | 28(59.6) | 24(77.4) | 32(65.3) | 20(69) | 20(54.1) | 32(78%) | |||
Smoking History | ||||||||||
Yes | 46(59.0) | 23(48.9) | 23(74.2) | 0.026 | 24(49) | 22(75.9) | 0.020 | 18(48.6) | 28(68.3) | 0.078 |
No | 32(41.0) | 24(51.1) | 8(25.8) | 25(51) | 7(24.1) | 19(51.4) | 13(31.7) | |||
ECOG PS | ||||||||||
0–1 | 49(62.8) | 37(78.7) | 12(38.7) | <0.001 | 42(85.7) | 7(24.1) | <0.001 | 37(100) | 12(29.3) | <0.001 |
2 | 29(37.2) | 10(21.3) | 19(61.3) | 7(14.3) | 22(75.9) | 0 | 29(70.7) | |||
NRS Scores | ||||||||||
4–6 | 62(79.5) | 37(78.7) | 25(80.6) | 0.837 | 40(81.6) | 22(75.9) | 0.542 | 29(78.4) | 33(80.5) | 0.818 |
7–10 | 16(20.5) | 10(21.3) | 6(19.4) | 9(18.4) | 7(24.1) | 8(21.6) | 8(19.5) | |||
Disease stage | ||||||||||
III | 34(43.6) | 24(51.1) | 10(32.3) | 0.101 | 27(55.1) | 7(24.1) | 0.008 | 22(59.5) | 12(29.3) | 0.007 |
IV | 44(56.4) | 23(48.9) | 21(67.7) | 22(44.9) | 22(75.9) | 15(40.5) | 29(70.7) | |||
ICIs types | ||||||||||
PD-1/PD-L1 | 75(96.2) | 45(95.7) | 30(96.8) | 0.817 | 47(95.9) | 28(96.6) | 0.888 | 35(94.6) | 40(97.6) | 0.496 |
Others | 3(3.8) | 2(4.3) | 1(3.2) | 2(4.1) | 1(3.4) | 2(5.4) | 1(2.4) | |||
ICIs lines of treatments | ||||||||||
1 | 38(48.7) | 27(57.4) | 11(35.5) | 0.058 | 30(61.2) | 8(27.6) | 0.004 | 25(67.6) | 13(31.7) | 0.002 |
≥ 2 | 40(51.3) | 20(42.6) | 20(64.5) | 19(38.8) | 21(72.4) | 12(32.4) | 28(68.3) | |||
ICIs combined medication | ||||||||||
ICIs+opioids | 36(46.2) | 26(55.3) | 10(32.3) | 0.046 | 29(59.2) | 7(24.1) | 0.003 | 24(64.9) | 12(29.3) | 0.002 |
ICIs+opioids+others | 42(53.8) | 21(44.7) | 21(67.7) | 20(40.8) | 22(75.9) | 13(35.1) | 29(70.7) | |||
opioids doses(mg/d) | ||||||||||
<30 | 38(48.7) | 27(57.4) | 11(35.5) | 0.058 | 28(57.1) | 10(34.5) | 0.125 | 22(59.5) | 16(39) | 0.071 |
≥ 30 | 40(51.3) | 20(42.6) | 20(64.5) | 21(42.9) | 19(65.5) | 15(40.5) | 25(61) | |||
Adverse event | ||||||||||
Grade1-2 | 58(74.4) | 39(83) | 19(61.3) | 0.032 | 43(87.8) | 15(51.7) | <0.001 | 37(100) | 21(51.2) | <0.001 |
Grade > 2 | 20(25.6) | 8(17) | 12(38.7) | 6(12.2) | 14(48.3) | 0 | 20(48.8) | |||
PD-L1 expression | ||||||||||
Positive | 24(30.8) | 16(34.0) | 8(25.8) | 0.441 | 15(30.6) | 9(31) | 0.969 | 12(32.4) | 12(29.3) | 0.762 |
Negative | 54(69.2) | 31(66.0) | 23(74.2) | 34(69.4) | 20(69) | 25(67.6) | 29(70.7) | |||
EGFR/ALK mutation | ||||||||||
Positive | 25(32.1) | 14(29.8) | 11(35.5) | 0.598 | 15(30.6) | 10(34.5) | 0.723 | 12(32.4) | 13(31.7) | 0.945 |
Negative | 53(69.7) | 33(70.2) | 20(64.5) | 34(69.4) | 19(65.5) | 25(67.6) | 28(68.3) | |||
Lung surgery | ||||||||||
Yes | 27(34.6) | 16(34) | 11(35.5) | 0.896 | 17(34.7) | 10(34.5) | 0.985 | 13(35.1) | 14(34.1) | 0.927 |
No | 51(65.4) | 31(66) | 20(64.5) | 32(65.3) | 19(65.5) | 24(64.9) | 27(65.9) |